PAR

4.65%

22.5¢ paradigm biopharmaceuticals limited..

Interview with Paul Rennie and Capital 51, page-12

First 12 Last

Share
Profile

Follow
oxxa23

6,055 Posts.

1165

18/03/21

20:45

Post #: 51878902
Share

Originally posted by Mozzarc ↑

Very insightful interview... (finally one where Paul could just speak without any time constraint/pressure!)

Many good topics covered, some included below. I know we can all listen but it's nice to see it in words too as a reference.

- What are the three main parts in our IND
- High level Trial composition
- Rationale for Dosing study
- Mechanics of Dosing study and subsequent pathway to Re-treatment study (006) follow on study
(Incredible amount of data will be generated from this to be added to the DB).
- Advantage of these comprehensive studies?
- Labelling and Market penetration discussion to maximise return on investment
- Chronic pain and what patients will endure to relieve it
- Paul's own personal story with iPPS
- Insight on "Imitation iPPS" and the issues of this.
- Format of iPPS for patient convenience (auto injector device)

- 008 study (Bio Marker study)
Why is it important?
Strategy of doing this now (as opposed to later)
Front line treatment potential
Durability & Improvement of joint (not just pain relief) to incorporate this into label
Biomarker discussion
Expected observations of 008
Good scientific coverage of some MOA of iPPS
Insight of getting such equivalent P3 data much before the P3 read-out albeit with a small study size (n=30)
Potential DMOAD data from this study to go to FDA and market with.
Commercial impact of DMOAD, reimbursement prices, possible increase in deal opportunities before P3 final readout/registration.

-TGA Provisional and First Revenues for the company
Reliance on data from 008 to demonstrate major new "theurpedic advance" in terms of timing and planning

- SAS pay per patient pricing discussion (ranging)
Treatment of Pain would result in a lower price range compared to 008 (if this shows DMOAD potential)

- Final pricing, to be determined approx Q3/Q4, before P3 trial is finalised

- MPS I and VI
Adjunctive therapy to ERT
Approx 200 cases in Brazil

- RRV
Similar symptoms to OA in chronic phase (approx 15% of cases)

- Heart failure : Commission of preclinical studies in France

-ARDS (pre clinical studies)

- Growth in terms of new hires/staff
Expansion of operations
Chairperson search ongoing

- Where do you see the company in 10 years?
Walk into any pharmacy and be able to treat OA with Zilosul
Other products available
Highly profitable and well respected Pharma Company with growth year on year

Focus on Marketability, Labelling and Market penetration, shows you the potential....
we know all of this, we have studied these, we have clues, we have our own patient (HC) stories and evidence from multiple research papers...but oh so nice to hear it being articulated clearly and in detail like this.

Well done to Scott.

Expand

@MisterMister might be worthwhile having a listen to this... or just read moz's comments on 008...

PAR Price at posting: $2.56 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

IMU

Imugene kicks off Australian trial for blood cancer treatment

Trump is President Again: What Does This Mean for Crypto?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

There are more pages in this discussion • 61 more messages in this thread...

First 12 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 22.5¢		Change 0.010(4.65%)		Mkt cap ! $78.73M

Open	High	Low	Value	Volume
22.0¢	23.5¢	21.5¢	$288.5K	1.279M

Buyers (Bids)

No.	Vol.	Price($)
6	130626	22.5¢

Sellers (Offers)

Price($)	Vol.	No.
23.0¢	60000	1

View Market Depth

No.	Vol.	Price($)
4	99263	0.225
1	110000	0.220
4	39604	0.215
11	304026	0.210
10	189997	0.205

Price($)	Vol.	No.
0.235	26540	1
0.240	92500	3
0.245	12000	1
0.250	109857	5
0.255	70880	2

Last trade - 16.10pm 08/11/2024 (20 minute delay)

PAR (ASX) Chart

Interview with Paul Rennie and Capital 51, page-12

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

Imugene kicks off Australian trial for blood cancer treatment

Trump is President Again: What Does This Mean for Crypto?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Flynn Gold reaches milestone exploration target for Golden Ridge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Interview with Paul Rennie and Capital 51, page-12

Top Stories

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

Imugene kicks off Australian trial for blood cancer treatment

Trump is President Again: What Does This Mean for Crypto?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Flynn Gold reaches milestone exploration target for Golden Ridge

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News